Evidence map›Paper›PMID 34045969›Full record

ReviewFrontiers in pharmacology2021

Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update.

Hrvoje Roguljic, Vjera Nincevic, Kristina Bojanic, Lucija Kuna, Robert Smolic, Aleksandar Vcev, Dragan Primorac, Andrijana Vceva, George Y Wu, Martina Smolic

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Predicting hepatitis C infection via machine learning.American journal of translational research · 2025
    Article
  9. Article
  10. Article
  11. Review
  12. La Tunisie medicale · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Hrvoje RoguljicFaculty of Medicine Osijek, J. J. Strossmayer University of Osijek, Osijek, Croatia.
Vjera NincevicFaculty of Medicine Osijek, J. J. Strossmayer University of Osijek, Osijek, Croatia.
Kristina BojanicFaculty of Medicine Osijek, J. J. Strossmayer University of Osijek, Osijek, Croatia.
Lucija KunaFaculty of Medicine Osijek, J. J. Strossmayer University of Osijek, Osijek, Croatia.
Robert SmolicFaculty of Medicine Osijek, J. J. Strossmayer University of Osijek, Osijek, Croatia.
Aleksandar VcevFaculty of Medicine Osijek, J. J. Strossmayer University of Osijek, Osijek, Croatia.
Dragan PrimoracFaculty of Medicine Osijek, J. J. Strossmayer University of Osijek, Osijek, Croatia.
Andrijana VcevaFaculty of Medicine Osijek, J. J. Strossmayer University of Osijek, Osijek, Croatia.
George Y WuDepartment of Medicine, Division of Gastroenterology-Hepatology, University of Connecticut Health Center, Farmington, CT, United States.
Martina SmolicFaculty of Medicine Osijek, J. J. Strossmayer University of Osijek, Osijek, Croatia.
University of Osijek · HRUConn Health · USUniversity of Split · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis C virus (HCV) infection is a systemic disease associated with multiple significant extrahepatic manifestations. Emerging studies indicate association between the HCV infection and a higher incidence of major adverse cardiovascular events such as: coronary artery disease, heart failure, stroke and peripheral artery disease, when compared to general population. Atherosclerosis is a common pathophysiologic mechanism of cardiovascular disease (CVD) development which is the leading cause of mortality in the Western world. Proposed mechanisms of HCV-induced atherosclerosis includes systemic inflammation due to the chronic infection with increased levels of pro-atherogenic cytokines and chemokines. Furthermore, it has been demonstrated that HCV exists and replicates within atheroschlerotic plaques, supporting the theory of direct pro-atherogenic effect of the virus. Direct acting antiviral agents (DAAs) represent a safe and highly effective treatment of HCV infection. Beside the improvement in liver-related outcomes, DAAs exhibit a beneficial effect on extra-hepatic manifestations of chronic HCV infection. Recently, it has been shown that patients with chronic HCV infection treated with DAA-based therapeutic regimes had a 43% reduction of CVD events incidence risk. Moreover, eradication of HCV with DAAs results in a significant positive effect on risk factors for cardiovascular disease, despite a general worsening of the lipid profile. This positive effects is mainly due to an improvement of endothelial function and glucose metabolism. Although DAA treatment is associated with a beneficial impact on cardiovascular events, further studies are needed to fully elucidate the mechanisms responsible.

Indexed as

cardiovascular diseasediabetes mellitusdirect antiviral agentsdyslipidemiahepatitis C virus

Identifiers

PMID34045969
PMCPMC8144519
OpenAlexW3160581114

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.